Maze Therapeutics CSBO Sells: Reading Insider Moves
When a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...
Target date funds adjust asset allocations over time toward a chosen retirement year, simplifying diversification and rebalancing for many savers.
19,808 articlesWhen a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...
A tiny 32 BTC sale by Saylor’s firm coincides with a wider pullback driven by major treasury holders and miner liquid...
Gold climbs to record highs while platinum remains weak, spotlighting a little-known platinum ETF that sits at the ce...
The Nasdaq 100 ETF is seeing its busiest month in years as traders chase SpaceX exposure, aided by new weighting rule...
Copper prices still surging have attracted buyers to the United States Copper Index Fund (CPER), a futures-based ETF....
As Innodata prepares to unveil its Q1 2026 results, investors want clarity on growth drivers, margins, and the path t...
The June S&P 500 quarterly rebalance could see new entrants like Marvell Technology, Reddit, and a mortgage-focused s...
When a company’s CFO sells a sizable block of stock, investors sit up and take notice. This article breaks down what ...
A high-level insider move follows a strong stock run. This article breaks down what the CFO’s sale signals, how to re...
In 2026, the equal-weight S&P 500 index has posted impressive breadth-driven gains, outpacing the cap-weight S&P 500 ...
Districts have spent tens of millions to ban phones in classrooms, but a sweeping study finds little to no improvemen...
Two overlooked satellite operators are quietly fueling the space economy in 2026, delivering real revenue and defense...